Julianne Overton
Director of Corporate Communications
Replay available
bioAffinity Technologies, Inc. (BIAF) Q4 2022 Earnings Call
bioAffinity Technologies, Inc. (NASDAQ: BIAF) Q4 2022 earnings conference call, held 2023-04-03. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Maria Zanes
President and Chief Executive Officer
Michael Edwards
Chief Financial Officer
Steve Silver
Analyst at Argus
Aaron Thomason
Private Investor
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Bioaffinity Technologies, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.029 -- 00:00:05.071 Good morning and welcome to the BioAffinity Technologies fourth quarter 2022 financial 00:00:05.071 -- 00:00:07.292 results conference call. 00:00:07.292 -- 00:00:09.713 All participants will be in listen-only mode. 00:00:09.713 -- 00:00:13.034 Should you need assistance, please signal conference specialist by pressing the star 00:00:13.034 -- 00:00:16.254 key followed by zero. 00:00:16.735 -- 00:00:20.057 After today's presentation, there will be an opportunity to ask questions. 00:00:20.057 -- 00:00:23.518 To ask a question, you may press star then on your telephone keypad. 00:00:23.518 -- 00:00:27.099 To withdraw your question, please press star then two. 00:00:27.099 -- 00:00:31.524 Please note this event is being recorded I'd like to turn the conference over to Julianne 00:00:31.524 -- 00:00:34.546 Overton, Director of Corporate Communications. 00:00:34.546 -- 00:00:36.926 Please go ahead. 00:00:37.128 -- 00:00:41.612 Thank you, Operator. Good morning, everyone, and welcome to today's conference call to 00:00:41.612 -- 00:00:47.337 discuss BioAffinity Technologies' fourth quarter and full year 2022 00:00:47.337 -- 00:00:51.560 financial results and our recent business progress. 00:00:51.560 -- 00:00:56.004 Please note that certain information discussed during today's call is covered under the 00:00:56.004 -- 00:01:01.673 Safe Harbor provisions. of the Private Securities Litigation Reform Act. 00:01:01.673 -- 00:01:06.856 We caution listeners that BioAuthenticity Technologies Management will be making forward-looking 00:01:06.856 -- 00:01:12.498 statements and that actual results may differ materially from those stated or implied 00:01:12.498 -- 00:01:17.480 by these forward-looking statements due to risks and uncertainties ass...